AEGLE THERAPEUTICS

Products

Category

Product

Brand

Description

Exosome Diagnostics, Therapeutics and Research Tools (BIO149E)

AGLE-102 (an investigational new drug)

A therapeutic composite of EVs, including exosomes, isolated from MSCs using Aegle Therapeutics’ proprietary EV harvesting technology. The lead indication for AGLE-102 is dystrophic epidermolysis bullosa (DEB), a rare pediatric disease resulting in severe skin blistering from minor friction. As of Jan 2024, Aegle Therapeutics was assessing the safety and efficacy of AGLE-102 in treating lesions in subjects with DEB (in phase 1/2A). In addition to DEB, the FDA has cleared Aegle’s IND for severe second-degree burns.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment